Quốc gia: Ai-len
Ngôn ngữ: Tiếng Anh
Nguồn: HPRA (Health Products Regulatory Authority)
ALLOPURINOL
PCO Manufacturing
300 Milligram
Tablets
1989-02-01
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zyloric 300 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 300 mg of allopurinol. Excipients: Contains Lactose For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Tablet Circular, white tablet, imprinted with ‘C9 B’ and a breakline on one side, plain on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Zyloric is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potinetially leading to acute uric acid nephropathy). The main clinical conditions where urate/uric acid deposition may occur are: o Idiopathic gout; o Uric acid lithiasis; o Acute uric acid nephropathy; o Neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously, or after cytotoxic therapy; o Certain enzyme disorders which lead to overproduction of urate, for example: - hypoxanthine-guanine phosphoribosyltransferase, including Lesch-Nyhan syndrome; - glucose-6-phosphatase including glycogen storage disease; - phosphoribosylpyrophosphate synthetase; - phosphoribosylpyrophosphate amidotransferase; - adenine phosphoribosyltansferase; Zyloric is indicated for the management of 2,8-dihydroxyadenine (2,8-DHA) renal stones related to deficient activity of adenine phosphoribosyltranferase. Zyloric is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed. IRISH MEDICINES BOARD ___________________________________________________________________________________________________________ Đọc toàn bộ tài liệu